Agile Therapeutics (AGRX) has shared an update.
Agile Therapeutics recently completed a significant merger, resulting in substantial changes to the company’s stock structure. As a consequence, all shares of Agile’s common stock were converted into a cash entitlement for shareholders, stock plans were terminated, and no new equity awards will be issued. This merger also ushered in a new board of directors and executive officers, signaling a fresh chapter for the company. Additionally, Agile’s stock will cease public trading and quoting on the OTCQB Market, marking the end of its presence as a publicly-traded entity.
Learn more about AGRX stock on TipRanks’ Stock Analysis page.
